Arrowhead Research | ARWR - Operating Profit



Arrowhead Research reported $-165550000 in Operating Profit for its fiscal quarter ending in June of 2025.


Operating Profit Change Date
Agios Pharmaceuticals USD -127056000 20.43M Jun/2025
Alnylam Pharmaceuticals USD -16199000 34.28M Jun/2025
Arrowhead Research USD -165550000 546.75M Jun/2025
Incyte USD 310.82M 105.66M Jun/2025
Ionis Pharmaceuticals USD 139.84M 285.84M Jun/2025
Ligand Pharmaceuticals USD 43.56M 79.78M Jun/2025
Merck USD 6.36B 494M Jun/2025
Moderna USD -907000000 143M Jun/2025
Novartis USD 4.86B 201M Jun/2025
Sarepta Therapeutics USD 115.58M 415.96M Jun/2025
TG Therapeutics USD 34.84M 26.22M Jun/2025
Ultragenyx Pharmaceutical USD -193567000 50.63M Jun/2025
Vertex Pharmaceuticals USD 1.15B 123.1M Jun/2025
Xencor USD -33172000 10.01M Jun/2025